Company Overview
Immutep Limited operates as a biotechnology entity focused on the development of novel Lymphocyte Activation Gene-3 related immunotherapies designed to treat cancer and autoimmune diseases within Australia. The company's primary business activity involves creating the eftilagimod alfa (efti or IMP321), which functions as a soluble LAG-3lg fusion protein derived from LAG-3 immune control mechanisms. This enterprise is situated within the Healthcare sector and specifically the Biotechnology industry, positioning it to capitalize on advancements in immunotherapy for oncological and autoimmune conditions. The company currently holds a market capitalization of $51.95M and reported annual revenue of $7.92M for the trailing twelve months, while the specific employee count is listed as N/A in available data. These financial scales indicate that Immutep functions as a mid-cap biotechnology firm with a specialized product pipeline, suggesting a position that relies heavily on R&D success rather than broad commercial diversification typical of larger established pharmaceutical giants.
Financial Health
For the trailing twelve months, the company reported a revenue of $7.92M, a net income of $-83,916,456, and an EBITDA of $-82,390,280. The substantial negative net income relative to the positive revenue stream reveals a cost structure where operating expenses and research costs significantly exceed current sales income, a common characteristic in the development phase of biotechnology assets. The free cash flow stands at $-35,678,096, which indicates that the company is burning through capital to fund its operations and product development rather than generating cash from its current business activities. Profitability metrics further illustrate this financial reality, with a gross margin of 0.0%, an operating margin of -763.7%, and a profit margin of 0.0%, signaling that current pricing or cost of goods sold structures do not yet support positive gross profitability, while operating losses are magnified by the high burn rate. On the balance sheet, the company holds $99.13M in cash against only $1.21M in debt, resulting in a debt-to-equity ratio of 1.22, which suggests a leveraged position relative to equity but is mitigated by a robust cash reserve that provides significant financial flexibility for future R&D spending. Liquidity is supported by a current ratio of 2.97, indicating that the company possesses nearly three times the current assets necessary to cover its short-term liabilities, thereby reducing immediate refinancing risks. However, the return on equity is -61.8% and the return on assets is -32.1%, metrics that reveal management is currently generating negative returns on the capital invested in the company, reflecting the ongoing investment phase rather than mature operational efficiency.
Valuation Assessment
Valuation multiples for Immutep Limited present a complex picture given the lack of traditional earnings, with a trailing P/E ratio of N/A and a forward P/E of -2.66. The negative forward P/E and the absence of a trailing P/E imply that the market is pricing the stock based on future earnings expectations that have not yet materialized, rather than historical performance. The price-to-book ratio is 7.64, which indicates a significant market premium over the company's book value, suggesting investors are willing to pay a high multiple for the potential value of its intellectual property and pipeline despite current losses. Alternative valuation metrics such as the price-to-sales ratio of 6.56 and an EV/EBITDA of -5.12 further highlight that the stock is valued primarily on its revenue generation capacity and asset potential rather than current profitability. In terms of trading range, the stock has a 52-week high of $3.53 and a 52-week low of $0.35, meaning the current price sits somewhere within this wide volatility band, reflecting the high risk-reward profile typical of speculative biotech equities. The beta value is 1.64, which means the stock exhibits higher price volatility relative to the broader market, moving more than 60% more aggressively than the market index in response to general market shifts.
Growth & Income
The company's financial trajectory shows a revenue growth year-over-year of 91.5%, while earnings growth is listed as N/A due to the company's lack of positive net income. Since earnings are not yet positive, the comparison between revenue and earnings growth rates is not applicable in the traditional sense, but the rapid revenue expansion implies successful scaling of commercial efforts or new product approvals. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This absence of a dividend payout indicates that the company retains all earnings, if any, and reinvests its capital resources directly back into research and development to accelerate the growth of its immunotherapy pipeline. Consequently, the overall growth and income profile is characterized by aggressive revenue expansion funded by cash reserves rather than shareholder distributions, aligning with the standard lifecycle of a biotechnology firm in the development or early commercialization stages.